



Community pharmacists' reflections on publication and dissemination of DHPCs

Jan De Belie
PGEU Professional Affairs Advisor

j.de-belie@pgeu.eu

www.pgeu.eu


PGEU Survey on Pharmacovigilance and Risk Minimisation

- The survey was open to all PGEU member organisations and was conducted between 31 March – 4th June 2021.
- 18 PGEU members (1 response per country) provided their responses to the survey:

Belgium	Czech Republic	France	Ireland	Norway	Slovenia
Croatia	Denmark	Germany	Italy	Portugal	Spain
Cyprus	Estonia	Greece	The Netherlands	Romania	United Kingdom


Dissemination sources: Professional associations & medicines agencies have a leading role in disseminating EMA safety communications

Who is disseminating EMA safety communications (e.g. DHPCs) to community pharmacies in your country? (Please tick all that apply)




Dissemination tools: Website and e-mails are the most commonly used dissemination tools

Through which channels are EMA safety communications (e.g. DHPCs) disseminated to community pharmacists in your country? (Please tick all that apply)




Dissemination process: Mixed satisfaction with the current dissemination process of EMA safety communications

How satisfied are you with the current dissemination process of relevant EMA pharmacovigilance / safety communications (e.g. DHPCs) to community pharmacists in your country (e.g. via your NCA)?




Content: The vast majority of respondents find the content of the communications rather or very useful

How useful do you find the content of the information of EMA pharmacovigilance / safety communications (e.g. DHPCs) for community pharmacists to inform patients in your country?




Timeliness: Mixed satisfaction with the timeliness of safety communications to pharmacists

How satisfied are you with the timeliness of the EMA pharmacovigilance / safety communications (e.g. DHPCs) to community pharmacists in your country in reference to the date since information on the safety concern is in the public domain?




Majority of countries feel that community pharmacists are adequately informed about aRMMs

Overall, do you feel that community pharmacists are adequately informed about the availability and use of additional risk minimisation materials (and which products require them) in your country?



In the majority of countries aRMMs are integrated in pharmacy dispensing software, but implementation degree varies

Are (additional) risk minimisation materials integrated in pharmacy dispensing software (e.g. pop-up alerts) in your country? Please provide details about the systems if applicable.



Main findings & Recommendations

Overall, the majority of community pharmacy organisations are rather satisfied with the dissemination process, content of information and timeliness of pharmacovigilance communications to pharmacists. However, several areas of improvement are identified:

- Ensure that dissemination of pharmacovigilance communications to pharmacists is **more tailored** (e.g. to national context), **targeted** (e.g. ≠ healthcare professionals), **frequent** (updates) and **complete** (e.g. early warning signals);
- **Create more structural collaboration** between EMA, national competent authorities (NCAs) and national pharmacy organisations.
- **Integrate information on additional risk minimisation measures**, including via relevant alerts, in **pharmacy dispensing software** so that the relevant information is accessible immediately at point of care and ensure that pharmacists can **record their interventions**;



THANK YOU!



Pharmaceutical Group of the European Union (PGEU)

-  Rue du Luxembourg 19, 1000 Brussels, Belgium
-  +32 (0)2 238 08 18
-  pharmacy@pgeu.eu
-  www.pgeu.eu